Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus VELOSEF 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX IN DEXTROSE 5 IN PLASTIC CONTAINER versus VELOSEF 125.
CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER vs VELOSEF '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftizoxime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
1-2 g IV every 8-12 hours; maximum 12 g/day
500 mg orally every 6 hours for uncomplicated infections; 1 g orally every 6 hours for more severe infections.
None Documented
None Documented
1.5–2 hours in normal renal function; extends to 20–30 hours in ESRD. Dose adjustment required for CrCl <50 mL/min.
Terminal elimination half-life: 0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in severe renal impairment (CrCl <10 mL/min)
Renal: 80–90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic